Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

Core Viewpoint - Avidity Biosciences intends to adjourn and reconvene its special meeting of stockholders to allow more time for the pro rata distribution of Atrium Therapeutics, Inc. common stock, which is a condition for the merger with Novartis AG [1] Group 1: Special Meeting Details - The special meeting is scheduled for February 23, 2026, at 10:00 a.m. Eastern time, and will be immediately adjourned [1] - The reconvened meeting will take place on February 26, 2026, at 10:00 a.m. Eastern time [1] - Stockholders who have registered do not need to re-register for the reconvened meeting, which will use the same virtual link [1] Group 2: Distribution and Merger Timeline - The distribution of Atrium Therapeutics common stock is expected to occur on February 26, 2026, with the merger closing anticipated on February 27, 2026 [1] - The completion of both the distribution and the merger is subject to closing conditions, including stockholder approval [1] Group 3: Stock Trading and Voting Information - Avidity's common stock will temporarily trade under the symbol "RNAM" on the Nasdaq Global Market starting from the distribution date [1] - The record date for the special meeting remains January 29, 2026, and proxies submitted will be voted at the reconvened meeting unless revoked [1] - Stockholders are encouraged to vote their shares now if they have not yet done so [1] Group 4: Company Overview - Avidity Biosciences focuses on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs), aimed at treating rare muscle diseases and genetic cardiomyopathies [1] - The company is advancing clinical development programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy [1]